In summary, we show that a high expression of CCR9, CCR10, and CXCR4 in the peripheral T lymphocytes of advanced lung cancer patients treated with anti-PD-1 immune checkpoint inhibitors is related to a poorer outcome, and that this effect was not observed in advanced cancer patients not receiving immunotherapy. The gene discussed is CXCR4; the disease is lung cancer.